• JAK Inhibitors Block Sensory Neuron Activation in RA: Mechan

  2026-04-20

  This study demonstrates that JAK inhibitors can directly prevent activation of human sensory neurons by rheumatoid arthritis (RA) synovial fluid, revealing a mechanistic basis for their superior pain relief over anti-TNF agents. The work employs transcriptomics, cytokine stimulation, and protein analysis to map cytokine-neuron interactions and JAK/STAT signaling in RA pain.

• Candida albicans EVs Inhibit Hyphal Growth via NRG1 Upregula

  2026-04-20

  This study reveals that high concentrations of Candida albicans extracellular vesicles (EVs) suppress hyphal development by upregulating the NRG1 transcriptional repressor. The findings clarify a key autoinhibitory mechanism influencing fungal pathogenicity and open new avenues for therapeutic modulation of virulence.

• RG108 DNA Methyltransferase Inhibitor: Protocols and Insight

  2026-04-19

  RG108 stands out as a potent DNA methyltransferase inhibitor, unlocking precise epigenetic gene regulation in both cancer and stem cell research. This article delivers actionable protocols, troubleshooting guidance, and experimental strategies, directly informed by cutting-edge studies and real-world lab experiences.

• LINC01278 Induces Autophagy and Suppresses Uveal Melanoma vi

  2026-04-18

  This study identifies LINC01278 as a novel autophagy-inducing long noncoding RNA that suppresses uveal melanoma progression by inhibiting the mTOR signaling pathway. Utilizing pharmacological modulators of autophagy, including 3-Methyladenine, the research delineates a mechanistic axis with potential implications for biomarker development and targeted therapy in ocular oncology.

• Perphenazine in Host-Directed Antibacterial and Neuropharmac

  2026-04-17

  Explore how Perphenazine, a dopamine D2 receptor antagonist, advances both schizophrenia research and host-directed antibacterial strategies through its unique multi-receptor actions and mitochondria-mediated cell death induction. This article reveals new mechanistic insights and assay guidance not covered in standard neuropharmacology reviews.

• Ordered DNA Frameworks Enhance Enzymatic Oligonucleotide Syn

  2026-04-16

  This study introduces a 3D tetrahedral DNA nanostructure (TDN) interface to improve enzymatic oligonucleotide synthesis (EOS), addressing spatial and kinetic limitations of traditional approaches. The results demonstrate higher yield, reduced deletion errors, and increased sequence fidelity, with implications for DNA storage and probe synthesis.

• Auranofin: Precision Thioredoxin Reductase Inhibitor Workflo

  2026-04-15

  Auranofin stands out as a high-specificity thioredoxin reductase inhibitor, unlocking advanced experimental designs in redox biology, cancer research, and cytoskeleton-dependent autophagy. This article unpacks stepwise protocols, real-world troubleshooting, and workflow enhancements that leverage APExBIO’s validated Auranofin for impactful, reproducible results.

• Enhancing In Vitro Drug Response Evaluation in Cancer Resear

  2026-04-14

  Schwartz's dissertation introduces a refined framework for distinguishing between proliferative arrest and cell death in vitro cancer drug assays. This work advances the interpretation of anti-cancer drug efficacy—such as with HDAC inhibitors like Belinostat—by clarifying how distinct assay metrics reveal separate biological effects.

• Optimizing Immunoblotting with ECL Chemiluminescent Substrat

  2026-04-13

  This article addresses core laboratory challenges in immunoblotting detection of low-abundance proteins, focusing on the ECL Chemiluminescent Substrate Detection Kit (Hypersensitive), SKU K1231. Drawing on scenario-driven Q&A, it provides actionable, evidence-based guidance for biomedical researchers seeking enhanced sensitivity, reproducibility, and workflow flexibility. The analysis helps labs evaluate vendor options and optimize western blot chemiluminescent detection using validated kit parameters.

• Berberine Hydrochloride: Translational Bridges in Metabolic

  2026-04-12

  Explore the multidomain applications of Berberine Hydrochloride in metabolic and inflammation research. This article uncovers new translational opportunities, highlighting AMPK-driven mechanisms and the latest insights into inflammasome modulation.

• BX795: Unraveling TBK1-Driven Immune Evasion and Autophagy C

  2026-04-12

  Explore how BX795, a potent PDK1 inhibitor, uniquely enables researchers to dissect TBK1-mediated immune evasion and autophagy in HBV infection. This article delivers novel insights grounded in recent breakthroughs, with practical guidance for advanced signaling studies.

• Adenosine Triphosphate in Cellular Metabolism Research

  2026-04-11

  Adenosine triphosphate (ATP) is indispensable for dissecting mitochondrial metabolism and purinergic signaling in advanced cellular research. This guide translates recent mechanistic breakthroughs into practical workflows, highlighting experimental design, troubleshooting, and best practices for leveraging APExBIO’s high-purity ATP.

• DMXAA (Vadimezan): Applied Workflows for Tumor Vasculature D

  2026-04-11

  DMXAA (Vadimezan) unlocks advanced experimental control over tumor vasculature, apoptosis, and immune pathways, making it a pivotal tool for translational cancer biology. This guide delivers practical protocols, troubleshooting strategies, and new insights from endothelial STING-JAK1 signaling, helping researchers maximize both mechanistic depth and reproducibility.

• Perphenazine as a Translational Research Catalyst: Mechan...

  2026-04-10

  This thought-leadership article articulates Perphenazine’s unique mechanistic portfolio—from dopamine D2 receptor antagonism to mitochondria-mediated cell death and host-directed antimicrobial strategies—offering translational researchers a roadmap for leveraging its polypharmacology. Integrating recent peer-reviewed findings, workflow guidance, and competitive positioning, this piece both contextualizes and expands current product narratives, positioning Perphenazine (SKU B6157, APExBIO) as a high-impact tool for advanced neuropharmacology, cell death, and immunology research.

• Perphenazine at the Translational Frontier: Mechanistic I...

  2026-04-09

  Explore how Perphenazine, a phenothiazine-derived dopamine D2 receptor antagonist, is transforming translational research in neuropharmacology and host-pathogen interactions. This thought-leadership article integrates mechanistic findings on dopamine signaling, mitochondria-mediated cell death, opioid tolerance suppression, and immune modulation via autophagy and ROS, providing actionable strategies for researchers. Going beyond conventional product summaries, we position APExBIO’s Perphenazine as a multidimensional research tool and highlight new frontiers in experimental design and clinical translation.

407 records 18/28 page Previous Next First page 上5页 1617181920 下5页 Last page